Genome Search in Celiac Disease  by Greco, Luigi et al.
Am. J. Hum. Genet. 62:669–675, 1998
669
Genome Search in Celiac Disease
Luigi Greco,1 Gino Corazza,2 Marie-Claude Babron,3,∗ Fabienne Clot,4,∗
Marie-Claude Fulchignoni-Lataud,4,∗ Selvaggia Percopo,1,∗ Patrizia Zavattari,5,∗
Faouzi Bouguerra,6 Colette Dib,7 Roberto Tosi,8 Riccardo Troncone,1 Alessandro Ventura,10
Wilma Mantavoni,11 Giuseppe Magazzu`,14 Rosanna Gatti,15 Rosanna Lazzari,12
Annamaria Giunta,16 Francesco Perri,18 Giuseppe Iacono,19 Ettore Cardi,9 Stefano de Virgiliis,21
Francesco Cataldo,20 Gianluigi De Angelis,22 Salvatore Musumeci,23 Roberto Ferrari,24
Fiorella Balli,25 Maria-Teresa Bardella,24 Umberto Volta,13 Carlo Catassi,26 Giuliano Torre,27
Jean-Franc¸ois Eliaou,28 Jean-Louis Serre,4 and Franc¸oise Clerget-Darpoux3
1Department of Pediatrics, University Federico II, Naples; 2Medicina Interna, L’Aquila, Italy; 3Institut Nationale de la Sante´ et de la Recherche
Me´dicale, Unit 155, Paris; 4Laboratoire de Cytoge´ne´tique et Ge´ne´tique Mole´culaire Humaine, University of Versailles, Versailles; 5Genetica
Umana, Dipartimento di Scienze Mediche, Novara, Italy; 6Unite´ de Ge´ne´tique Epide´miologique, Hoˆpital d’Enfants and Institut National de la
Sante´ Publique, Tunis; 7Ge´ne´thon, Evry; 8Biologia Cellulare, Consiglio Nazionale delle Richerche, and 9Department of Pediatrics, University
of Roma La Sapienza, Rome; 10Department of Pediatrics, University of Pisa, Pisa; 11Laboratorio di Analisi, Ospedale Maggiore Bologna,
12Department of Pediatrics, University of Bologna, and 13Il Istituto di Semeiotica Medica, Bologna; 14Department of Pediatrics, University of
Messina, Messina; 15Istituto Gaslini, Genoa; 16Department of Pediatrics, University of Milan, and 17Istituto di Scienze Mediche, Milan; 18Casa
Soccorso della Sofferenza, San Giovanni Rotondo, Italy; 19Department of Pediatrics “Di Cristina” and 20Department of Pediatrics “Lancia di
Brolo,” University of Palermo, Palermo; 21Istituto di Clinica e Biologia dell’Eta` Evolutiva, Cagliari, Italy; 22Department of Pediatrics, University
of Parma, Parma; 23Department of Pediatrics, University of Catania, Catania; 24Department of Pediatrics, University of Florence, Florence;
25Department of Pediatrics, University of Modena, Modena; 26Department of Pediatrics, University of Ancona, Ancona; 27Istituto Burlo
Garofolo, Trieste; and 28Institut Nationale Sante´ E´tude et Recherche Me´dicale, Unit 291, Montpellier, France
Summary
Celiac disease (CD), a malabsorption disorder of the
small intestine, results from ingestion of gluten. The
HLA risk factors involved in CD are well known but
do not explain the entire genetic susceptibility. To de-
termine the localization of other genetic risk factors, a
systematic screening of the genome has been undertaken.
The typing information of 281 markers on 110 affected
sib pairs and their parents was used to test linkage. Sys-
tematic linkage analysis was first performed on 39 pairs
in which both sibs had a symptomatic form of CD. Rep-
lication of the regions of interest was then carried out
on 71 pairs in which one sib had a symptomatic form
and the other a silent form of CD. In addition to the
HLA loci, our study suggests that a risk factor in 5qter
is involved in both forms of CD (symptomatic and si-
lent). Furthermore, a factor on 11qter possibly differ-
entiates the two forms. In contrast, none of the regions
recently published was confirmed by the present
screening.
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Introduction
Celiac disease (CD) is a permanent immunomediated
intolerance to the gluten-composing proteins of wheat,
barley, and rye. The population prevalence in the West-
ern world is between 0.2% and 0.5% (Catassi et al.
1994). The prevalence probably represents an underes-
timate, because not all cases of CD are symptomatic.
Indeed, a variety of clinical features result from gluten
consumption in genetically predisposed individuals,
ranging from absence of significant symptoms to life-
threatening health complaints (Troncone et al. 1996). A
unifying classification of the clinical features was pro-
posed by the European Society of Paediatric Gastroen-
terology and Nutrition (ESPGAN) in 1970 (Meeuwisse
1970) and has since been updated (Walker-Smith et al.
1990). Malabsorption with chronic diarrhea, iron de-
ficiency and growth retardation are often the main symp-
toms. At the histological level, the small bowel presents
various degrees of mucosal lesions and intraepithelial
lymphocyte invasion (Marsh 1992). Enteropathy-asso-
ciated T-cell lymphoma and small bowel, pharyngeal, or
esophageal cancer can develop. Extraintestinal manifes-
tations of CD, such as neurological symptoms, epilepsy,
posterior cerebral calcifications, dermatitis herpetifor-
mis, and various associated or subsequent disorders, are
sometimes present (Ma¨ki and Collin 1997). The auto-
immune process leads to CD-specific antigliadin, antir-
eticulin, and antiendomysium antibodies.
CD has a multigenic and multifactorial origin: the
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existence of a genetic predisposition is supported by a
10% prevalence in first-degree relatives and a
80%–100% concordance in MZ twins, compared with
20% in DZ twins (Sollid and Thorsby 1993). A strong
predisposing factor lies in the HLA class II region. Eighty
percent to 95% of celiac patients carry the same DQ
heterodimer, DQA1*0501 DQB1*0201, encoded in cis,
in DR3 individuals, or in trans, in DR5/DR7 hetero-
zygous individuals (Sollid et al. 1989). All of the re-
maining cases carry a DR heterodimer encoded by the
genes DRA1 and DRB4 (Bouguerra et al. 1997; Clerget-
Darpoux et al. 1997). However, only part of the familial
aggregation is explained by the HLA component (Risch
1987; Petronzelli et al. 1997), which suggests the pres-
ence of additional non-HLA genetic risk factors. To find
other factors of genetic susceptibility, we collected a large
sample of CD-affected sib pairs with living parents, and
we screened the whole genome by testing linkage with
polymorphic genetic markers.
Families, Material, and Methods
Family Sample
A sample of Italian sib pairs was ascertained by iden-
tification of one sib who had a symptomatic form of
CD, according to Societa` Italiana di Gastroenterologia
ed Epatologia Pediatrica criteria. The other sib could
present one of two clinical forms of CD: a symptomatic
form characterized by villous atrophy, antiendomysium
antibodies, and clinical symptoms (diarrhea, growth fail-
ure, or vomiting) or a silent form characterized by villous
atrophy and antiendomysium antibodies but without
clinical symptoms. Each sib was diagnosed according to
the criteria set by the ESPGAN (Walker-Smith et al.
1990). Families in which patients were not diagnosed
through a small-bowel biopsy were not considered for
admission. Ethical approval was granted by the National
Scientific Committee of the Italian Celiac Society. In-
formed consent was obtained from all members of the
family under study.
One hundred five families with living parents and ei-
ther two affected sibs (98 families) or three affected sibs
(7 families) were thus recruited. Note that, after verifi-
cation of Mendelian segregation for each marker, two
families were excluded from the sample, giving rise to
110 independent affected sib pairs. They are distin-
guished according to their clinical-symptomatic or silent-
form status: S1 pairs are those in which both sibs have
a symptomatic form (39 pairs), and S2 pairs are those
in which one sib has a symptomatic form and the other
a silent form (71 pairs).
Microsatellite Genotyping
The affected sibs and their parents were typed, over
the whole genome, by use of 254 microsatellite poly-
morphic markers, from the fluorescent panel of Ge´ne´-
thon, with an average distance of 13 cM (Dib et al.
1996). PCR amplifications were performed in a final
volume of 15 ml, containing 30 ng of genomic DNA,
0.33 mM of each primer, 0.16 mM dNTPs, 10 mM Tris
pH 9, 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton, 0.01%
gelatin, and 0.03 IU of Taq polymerase (Perkin Elmer)
(Ginot et al. 1996). Reactions were performed by means
of a “hot-start” procedure: Taq polymerase was added
to the reaction mixtures after a first denaturation step
(5 min at 96C). This was followed by 33 cycles of in-
creasing stringency: denaturation (40 s at 94C), an-
nealing from 70C to 57C, 30 s without elongation step.
After completion of the PCR reaction, T4 DNA poly-
merase (0.05 UI), 3′–5′ activity (Biolab) was applied at
37C for 30 min. PCR reaction products were pooled,
and denatured aliquots were separated on 5% denatur-
ing polyacrylamide gels. Data were collected with the
373A sequencer (ABI) and genotyped with Genescan
672 and Genotyper software (ABI).
Five regions on chromosomes 6, 7, 11, 15, and 22
were more densely typed, because some evidence of link-
age had been suggested by Zhong et al. (1996). Twenty-
seven markers were amplified by the “classic method”
(Gyapay et al. 1994). PCR amplifications were per-
formed in 50-ml reaction mixtures that contained 40 ng
of genomic DNA, 50 pmol of each primer, 125 mM
dNTPs, 10 mM Tris pH 9, 50 mM KCl, 1.5 mM MgCl2,
0.1% Triton X-100, 0.001% gelatin, and 0.06 IU of Taq
polymerase (Perkin Elmer). Amplifications were carried
out by use of the hot-start procedure, with a denatur-
ation step (5 min at 96C), after which 35 cycles of
denaturation (94C for 40 s) and annealing (55C for
30 s) were performed, followed by a final elongation
step (2 min at 72C). For each DNA sample, three am-
plification products from different markers were loaded
together into single lanes of 6% polyacrylamide–8 M
urea denaturing gels. After migration, DNA was trans-
ferred from the gel to a Hybond N nylon membrane
(Amersham) by a contact blotting procedure. The mark-
ers were then revealed by hybridization with the micro-
satellite probe, which was peroxidase labeled (Amer-
sham) and exposed to autoradiographic X-ray films.
Overall, 281 microsatellite markers were studied.
Data Analysis
Linkage was tested in accordance with the maximum-
likelihood–score (MLS) approach (Risch 1990b). The
identity-by-descent (IBD) distribution (proportion Z2,
Z1, or Z0 of pairs sharing 2, 1, or 0 allele(s) IBD, re-
spectively) can be estimated, given the observations on
the marker genotype. The likelihood of this IBD estimate
is then compared with the one expected under no linkage
( , , ). The MLS is the decimal logarithm of the like-1 1 14 2 4
lihood ratio. Information on several linked markers can
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Figure 1 MLS scores obtained for each chromosome in the S1 sample (both sibs symptomatic CD).
be gathered simultaneously. The MLS can be computed
for different locations relative to the markers. The MLS
does not depend on the marker allele frequencies when
the parents are typed, which is the case in the present
study.
The MAPMAKER-SIBS program (Kruglyak and
Lander 1995) calculates, for a sample of affected sib
pairs, the MLS and the corresponding maximum-like-
lihood estimate of the IBD vector.
When the test is applied for one locus, an MLS of 1.3
gives evidence for linkage with a type I error of 1%
(Holmans 1993). In case of systematic screening of the
genome, the type I error for such a value is much higher.
The correction due to the numerous (281) points ana-
lyzed drastically reduces the power to detect involved
factors. To avoid losing power while keeping a reason-
able type I error, we performed a two-step analysis. In
a first phase, we calculated the MLS at each marker locus
for the S1 sample. Then, for each marker position at
which the MLS was 11.3, we calculated the MLS in the
S2 sample, not only for this marker but also for the two
flanking markers. Indeed, the confidence interval is large,
and the maximum MLS does not necessarily indicate the
true location of the risk factor (Kruglyak and Lander
1996). The significance of the MLS test for each region
tested was assessed through simulations. The maximum
MLS obtained in the S2 sample for the three markers
of a considered replication region is denoted by V. Sim-
ulations of segregation of the three markers under study
were based on the assumption of no linkage between
the disease and the markers. One thousand replicates
were generated. We then calculated the number of times
the MLS for these three markers exceeded the value V.
This calculation gives the type I error for this region.
In case of nonreplication in the S2 sample, two ex-
planations could be given: either results in S1 are due
to random deviations, or the two samples are hetero-
geneous. Therefore, for each region considered in the
second step, the homogeneity of the two samples was
tested. The following Q values were computed for the
three markers of the region: Q  2Ln10{MLS(S1
.S2) [MLS(S1)MLS(S2)]}
The significance of the maximum Q value (Qmax) was
assessed by bootstrap. The bootstrapping was performed
on the genotypes at the three markers of the original
sample (S1  S2). The sample was then divided each
time in two subsamples of 39 sib pairs (equivalent to
S1) and of 71 sib pairs (equivalent to S2). Two thousand
bootstraps were realized, and the corresponding value
of Qmax was evaluated for each. The significance of the
test is obtained by the number of times Q exceeds the
observed Qmax value.
Risch (1990a) introduced a measure of the contri-
bution of a genetic risk factor, denoted l. Given the
marker observation, exclusion of those areas of the ge-
nome that are unlikely to contain a genetic risk factor
corresponding to a given relative risk l* is possible by
comparing the likelihood of to the likelihood ofl  1
l*. When presence of a genetic factor with a relative
risk xl* has been excluded, the existence of a risk locus
in the region is still possible, but its associated risk must
be !l*.
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Figure 2 Distribution of the MLS scores for chromosome 6. Solid line: total sample (S1  S2); broken line: S1 sample (both sibs
symptomatic CD). The dots on the abscissa indicate the positions and names of the markers used in the analysis.
Results
Systematic Screening
In the S1 sample, the MLS values were computed for
each chromosome, at each marker position, taking into
account the genotype information available on all the
chromosome markers. Figure 1 displays, for each chro-
mosome, the maximum of these MLS values. Note that
the type I errors that correspond to an MLS value be-
tween markers are not the same as those at the exact
marker locations. Eichenbaum-Voline et al. (1997)
showed that they are greater between markers. Conse-
quently, only values at marker locations are interpreted
in this study.
The MLS in the S1 sample exceeds 1.3 for three
regions: 6p21 ( ), 5qter ( ), andMLS  3.5 MLS  1.8
11qter ( ). The MLS curves (dashed line) forMLS  1.8
these three chromosomes are shown in figures 2, 3, and
4, respectively. The highest MLS is obtained for the 6p21
(HLA) region, which corresponds to the effect of the
well-known HLA component.
Figure 2 displays the MLS results in the HLA region
for S1 (dashed curve) and the global sample (solid curve).
The maximum MLS are 3.5 and 6.0, respectively. There
is no evidence of heterogeneity between S1 and S2. The
global IBD estimate is ; ; .Z  .50 Z  .41 Z  .092 1 0
The first step of the analysis suggests the existence of
other factors in two new regions. Therefore, in the S2
sample, the MLS were computed only for three markers
in these two regions.
On the region 5qter, the three markers used for rep-
lication in the S2 sample were D5S2069, D5S2111, and
D5S2006. An MLS value of 1.0 was obtained for
D5S2006 (with a P value, assessed by simulations, of
.04). There is no evidence for heterogeneity between S1
and S2 for the 5qter markers ( ; ). TheQ  3.6 P  .18max
MLS value on the global sample (S1  S2) is 2.0 (solid
line in fig. 3) at the terminal marker with an IBD estimate
; ; .Z  .42 Z  .39 Z  .192 1 0
On the region 11qter, the three markers used for rep-
lication in the S2 sample are D11S4142, D11S934, and
D11S910. In contrast to the 5qter region, evidence for
linkage was not replicated in the S2 sample for the
11qter region (MLS  0 for the three markers). In ad-
dition, there is evidence of heterogeneity between S1 and
S2 ( ; ). This means that either theQ  6.14 P  .03max
results for S1 cannot be interpreted as evidence for link-
age or there exists, in 11qter, a risk factor that differ-
entiates the symptomatic and silent forms of CD.
Nonreplication of Regions Already Published
In a sample of Irish sib pairs, Zhong et al. (1996)
found evidence for linkage for five new chromosome
locations apart from HLA: 6p23, 7q31, 11p11, 15q26,
and 22cen. Table 1 provides, for these five locations, the
MLS of Zhong et al., our MLS on the global sample (S1
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Figure 3 Distribution of the MLS scores for chromosome 5. Solid line: total sample (S1  S2); broken line: S1 sample (both sibs
symptomatic CD). The dots on the abscissa indicate the positions and names of the markers used in the analysis.
Table 1
Genomic Regions of Interest (Zhong et al. 1996): Multipoint MLS




Zhong et al. (1996) Present Study l
6p23 4.66 1.0 )
7q31 2.99 0 1.6
11p11 3.92 0 1.8
15q26 2.12 .5 1.8
22cen 2.69 0 1.6
 S2), and the l value for which the likelihood ratio is
below the traditional criterion of 2. For the last four
locations, the presence of a risk factor with a relative
risk 11.8 is excluded in our study. For the region 6p23,
the MLS of 1.0 at D6S443 corresponds, in our data, to
what is expected for a risk factor located in HLA. Indeed,
given the well-known HLA determinism and the cor-
responding HLA IBD vector (0.50, 0.41, 0.09), it is pos-
sible to calculate the expected IBD vector at D6S443 (28
cM from HLA). The observed IBD at D6S443 (0.32,
0.49, 0.19) is very close to the expected one (0.35, 0.47,
0.18).
Although our study does not confirm the regions pro-
posed by Zhong et al., note that, in contrast to the
marker in 5qter for which we obtained a MLS of 2.0 in
S1, the MLS in Zhong et al. was 0.9 (fig.1a in their
article). This is not at all inconsistent with our suggestion
of a susceptibility locus in this region.
In addition to our linkage analysis, it was possible to
estimate the typing error rate through the additional
analysis of 15 MZ twins. The rate was estimated to be
1%. Our study also allowed more accurate estimation
of the allelic frequencies of Ge´ne´thon panel-D micro-
satellites, through genotyping of all 236 parents (472




Our study confirms the implication of HLA as a risk
factor for CD. No heterogeneity could be found between
the S1 and S2 samples. This result shows that the HLA
component is not a factor that differentiates the symp-
tomatic and silent forms of CD.
Beyond the well-known factor in the HLA region
(6p21), our study suggests that a risk factor in the ter-
minal portion of chromosome 5 (5qter) is involved in
both symptomatic and silent forms of CD. The results
of Zhong et al. (1996) for the same region provide ad-
ditional evidence for a risk factor in this region.
For the 11qter region, our data cannot discriminate
between the two hypotheses: presence of a susceptibility
factor that is involved in the symptomatic forms of CD
only, or S1 as the result of chance.
In a sample of Irish sib pairs, Zhong et al. (1996)
found some evidence for linkage for five new chromo-
some locations apart from HLA: 6p23, 7q31, 11p11,
15q26, and 22cen. In a recent study, Houlston et al.
(1997) found no significant evidence in favor of linkage
to CD for these regions, except for chromosome 15. In
our study, the presence of a risk factor with a relative
risk 11.8 in the regions 15q26 and 11p11, and 1.6 in
the regions 7q31 and 22cdn, was excluded. On the as-
sumption of the presence of risk factors in these regions
with relative risks !1.8, MLS values as high as those
obtained by Zhong et al., in a sample of 45 dependent
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Figure 4 Distribution of the MLS scores for chromosome 11. Solid line: total sample (S1  S2); broken line: S1 sample (both sibs
symptomatic CD). The dots on the abscissa indicate the positions and names of the markers used in the analysis.
sib pairs, are not expected. Two explanations may be
given to explain this discrepancy: either the genetic com-
ponent of CD is different in the Irish and Italian pop-
ulations, or the high MLS values obtained by Zhong et
al. are due to the particular familial structure they stud-
ied. Indeed, among their 45 sib pairs, 31 belong to just
three nuclear families. Babron et al. (1997) showed that,
when parents are untyped, inclusion of a large number
of sib pairs that belong to a few nuclear families may
lead to artificially high values of MLS. In particular, it
may explain the second MLS peak on chromosome 6 in
6p23. A replication study in a different sample is
planned, to confirm the presence of a risk factor in 5qter
and to demonstrate that a risk factor in 11qter differ-
entiates symptomatic and silent forms of CD.
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